Everolimus

185 interactions 1 explained in plain English 567 cited references

Also sold as: Afinitor Afinitor Disperz® Afinitor® Torpenz Zortress Zortress®

About Everolimus

Everolimus (Afinitor) is used to treat advanced renal cell carcinoma (RCC; cancer that begins in the kidneys) that has already been treated unsuccessfully with other medications. Everolimus (Afinitor) is also used to treat a certain type of advanced breast cancer that has already been treated with at least one other me… Read the full Everolimus drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Bacillus Of Calmette And Guerin Vaccine, Live Yellow Fever Vaccine Typhoid Vaccine Ensitrelvir Varicella Virus Vaccine, Live Dengue Tetravalent Vaccine, Live

13 Contraindicated 160 Major 12 Moderate

All (185) Contraindicated (13) Major (160) Moderate (12)

Contraindicated

Everolimus Bacillus Of Calmette And Guerin Vaccine, Live An increased risk of infection by the live vaccine Details Everolimus Dengue Tetravalent Vaccine, Live An increased risk of infection by the live vaccine Details Everolimus Ensitrelvir Increased CYP3A/P-gp substrate exposure and an increased risk of adverse reactions Details Everolimus Levoketoconazole Recorlev Increased exposure of CYP3A4/P-gp substrate Details Everolimus Measles Virus Vaccine, Live An increased risk of infection by the live vaccine Details Everolimus Mifepristone Korlym Increased everolimus exposure and an increased miFEPRIStone exposure Details Everolimus Mumps Virus Vaccine, Live An increased risk of infection by the live vaccine Details Everolimus Ritonavir Norvir Increased everolimus exposure and an increased risk of immunosuppressant-related adverse effects Details Everolimus Rubella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Everolimus Smallpox Monkeypox Vaccine An increased risk of infection by the live vaccine Details Everolimus Typhoid Vaccine Typhim VI® An increased risk of infection by the live vaccine Details Everolimus Varicella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Everolimus Yellow Fever Vaccine Stamaril An increased risk of infection by the live vaccine Details

Major

Everolimus Lisinopril Prinivil Increased risk of angioedema Details Everolimus Abrocitinib Cibinqo Increased exposure of P-glycoprotein substrate Details Everolimus Asciminib Scemblix Increased exposure to CYP3A4/P-gp substrates and increased risk of CYP3A4/P-gp substrates-related adverse effects Details Everolimus Belumosudil Rezurock Increased P-gp substrate exposure Details Everolimus Benazepril Lotensin Increased risk of angioedema Details Everolimus Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Everolimus Captopril Capoten® Increased risk of angioedema Details Everolimus Elacestrant Orserdu Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Everolimus Enalapril Epaned Increased risk of angioedema Details Everolimus Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Everolimus Encorafenib Braftovi Reduced everolimus exposure and reduced efficacy of everolimus Details Everolimus Erdafitinib Balversa Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Everolimus Adagrasib Krazati Increased exposure to CYP3A/P-gp substrates Details Everolimus Adenovirus Vaccine Type 4, Live An increased risk of infection by the live vaccine Details Everolimus Adenovirus Vaccine Type 7, Live An increased risk of infection by the live vaccine Details Everolimus Alfentanil Increased ALfentanil exposure and an increased risk of respiratory depression Details Everolimus Apalutamide Erleada Reduced everolimus exposure and reduced efficacy of everolimus Details Everolimus Artemether Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Everolimus Avacopan Tavneos Increased exposure to CYP3A4 substrate Details Everolimus Belzutifan Welireg Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Everolimus Berotralstat Orladeyo Increased everolimus exposure Details Everolimus Boceprevir Increased everolimus exposure Details Everolimus Cannabidiol Epidiolex Increased everolimus exposure Details Everolimus Carbamazepine Carbatrol Reduced everolimus exposure and reduced efficacy of everolimus Details Everolimus Ceritinib Zykadia Increased exposure of CYP3A substrate Details Everolimus Cholera Vaccine Ipol An increased risk of infection by the live vaccine Details Everolimus Clarithromycin Biaxin Increased everolimus exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.